Epizyme, Inc. (EPZM) is a Cambridge, MA-based development-stage biopharmaceutical company focused on bringing novel epigenetic oncology therapies to the market.
Being a development-stage company, Epizyme does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
The company’s top line comprises collaboration revenues only. Epizyme has partnerships with a number of companies including Celgene, Eisai and Glaxosmithkline. These agreements not only validate its proprietary product platform but also provide it with funds in the form of upfront, milestone and other payments.
In Jul 2015, Epizyme amended its agreement with Celgene to extend the research collaboration between the two companies for at least three additional years. Under the agreement, Celgene gained the option to license histone methyltransferase inhibitors being developed by Epizyme against three predefined targets. Per the amendment, Epizyme received a $10 million extension fee from Celgene in exchange for an option to individually license the global rights for two of the targets and ex-US rights for the third target.